T H E O F F I C I A L D A I LY N E W S PA P E R O F T H E A S C O A N N U A L M E E T I N G

ASCO DAILY NEWS SATURDAYJUNE 5, 2010

2010 ANNUAL MEETINGCHICAGO, IL

ISSUE 1 • SECTION A

INSIDE THIS SECTION

2A2010 ASCO Special Awards Recognize Leaders3AEditor’s Welcome4ATrack CME Credits on ASCO UniversityTM

New Session Discusses Ongoing Trials

6AASCO Issues PCO on Hepatitis B Screening7AePosters Enhance Annual Meeting Experience 8AInteractive Session Utilizes Social Networking9AThe ASCO Post DebutsAnnual Meeting Program Updates

10ADr. Isabelle Bedrosian Receives ACRAAbout ASCO Daily News12AResearch Teams Receive $1.35 MillionVisit the Networking and Connection Hub14AEnvironmental Efforts at ASCO’s Annual MeetingeGuideTM Mobile Application Available

By Douglas W. Blayney, MD2009-2010 ASCO President

Throughout the past 8 years, contin-ued innovation in our research labo-ratories, clinics, outpatient treatment

centers, patients’ bedsides, and communities — all the places where we do our work — has resulted in sustained decreases in cancer death rates. As oncology professionals, we are committed to delivering high-quality care in all of these venues and to advancing innova-tive treatments, practices, and approaches.

And although “Advancing Quality through Innovation” is the theme of the 2010 ASCO Annual Meeting, we hope to continue to dis-cover and discuss the latest innovations in re-search, quality, practice, and technology well after the Meeting’s end.

The 2010 Annual Meeting will feature sev-eral new initiatives and programs that promise to advance quality and promote innovation and technology. We will be enhancing audi-ence participation through this afternoon’s innovative Education Session, “Management of Side Effects of the Treatment of Colorectal

Cancer,” which will serve as a pilot program encouraging at-tendees to send questions to par-ticipating faculty by text, e-mail, or Twitter. (For more information on this session, see the ar-ticle on page 8A of

this issue of ASCO Daily News.)This year, a new scientifi c poster session —

the Trials in Progress Poster Session — has been created to facilitate awareness and dia-logue about open, ongoing clinical trials. It differs from other Poster Sessions in that its focus is on the background of the science be-hind the trial; outcomes data and results will not be presented. The Trials in Progress Post-er Session will promote discussion among trial investigators, encourage recruitment of new investigators or sites, and stimulate dis-cussion of successor or confi rmatory trials (For more information on the Trials in Progress

Poster Session, see the article on page 4A of this issue of ASCO Daily News).

Many other sessions offered as part of the Meeting’s educational program will explore the Meeting’s theme, including “From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation — An ASCO/American Association for Cancer Re-search Joint Session;” “Future Treatment Approaches toward Colorectal Cancer: New Therapeutic Pathways, New Targets;” “Clos-ing the Loop: Evidence, Guidelines, Report-ing, and Quality;” and “How to Use Data to Improve Practice: Nexus of Quality and Effi -ciency.” Attendees can make use of the online Meeting Planner (meetingplanner.asco.org) for detailed information about these sessions, including speakers and presentation times.

We’re also proud to be presenting sever-al new ASCO Cancer Foundation® awards and grants to improve cancer care and fund research. These new awards and grants in-clude the Advanced Clinical Research Award in Colorectal Cancer; Comparative Effec-tiveness Research Professorship in Breast Cancer; Improving Cancer Care Grant; and

Long-term International Fellowship. Also new this year, stemming from last

year’s publication choice program, attend-ees can choose to receive the 2010 ASCO Educational Book and the 2010 ASCO Annual Meeting Proceedings Part I in print or on a USB drive. A quick reference guide, which includes the Annual Meeting Program Cal-endar of Events, is included on the USB to help attendees plan their Meeting experience. This content will also be available online as an “eTote” for all registered attendees through June 18, 2010 (www.asco.org/eTote2010).

We are excited to bring ASCO’s Annual Meeting back to the beautiful city of Chicago this year. You may know Chicago as “The Windy City,” but it is also nicknamed the “The City That Works.” With its warm hos-pitality and world-class cultural attractions — not to mention a state-of-art convention center in McCormick Place — Chicago is in-deed a city that works for ASCO.

I look forward to joining the oncology community for the 2010 ASCO Annual Meet-ing as we work together to advance quality cancer care for our patients.

2010 Annual Meeting: Advancing Quality, Promoting Innovation

Douglas W. Blayney, MD

At the 2010 ASCO Annual Meeting, nearly 30,000 oncologists from around the world will assemble to take advan-

tage of an educationally and scientifi cally ro-bust program. At an event of this magnitude, easy navigation of both the Meeting program itself and McCormick Place is crucial to attend-ees’ ability to fulfi ll their varied professional interests. To maximize the onsite experience, several new publications and initiatives are in place to ensure that attendees can easily locate the sessions and events of greatest interest to them. Listed below are some of the resources ASCO offers to help attendees plan, navigate, and enhance their Annual Meeting experience.

Navigating the Meeting ProgramThe Preliminary Annual Meeting Program

was mailed to all pre-registered attendees and ASCO members in April. The Annual Meeting Program (formerly the Annual Meeting Pocket Program) contains updated information and was distributed onsite to at-tendees in their tote bags. The Annual Meet-ing Program contains detailed information on the educational and scientifi c program, including session dates, faculty, times, and locations. Additionally, abstract titles for Oral Abstract, Poster Presentation, and Gen-eral Poster Sessions are included. Attendees will also fi nd a Calendar of Events as well as indices of Scientifi c Sessions, Special Ses-sions, and Clinical Science Symposia in this publication.

The electronic version of this product, the online Meeting Program (meetingplanner.

asco.org), contains the most complete and up-to-date program information in addition to all program listings of sessions and abstract titles, which can be searched by track, session type, date, key word, abstract number, or speaker. Attendees can use this tool to build an itinerary and export it to an electronic cal-endar, such as Microsoft Outlook.

Valuable Onsite Resources ASCO provides many onsite resources to

help attendees optimize their Meeting expe-rience, and the Society has worked to make the Oncology Professionals Hall (formerly the Exhibit Hall) an experience that blends indus-try and science with educational networking

See Resources, Page 7A

Resources, Products Optimize Experience for 2010 Annual Meeting Attendees

2A • ASCO Daily News • SATURDAY, JUNE 5, 2010

The Society will honor 37 individuals whose vigorous research, attentive clinical care, and tireless advocacy

for patients have made signifi cant inroads in the fi ght against cancer. Throughout the Annual Meeting, ASCO will present Special Awards to these recipients, who were chosen by the Special Awards Selection Committee for their outstanding contributions to can-cer care and to the Society.

The 10 Special Awards being recognized at this year’s Meeting are as follows:• David A. Karnofsky Memorial Award and

Lecture• Science of Oncology Award and Lecture• ASCO-American Cancer Society Award

and Lecture• Gianni Bonadonna Breast Cancer Award

and Lecture• B. J. Kennedy Award and Lecture for

Scientifi c Excellence in Geriatric Oncology• Pediatric Oncology Award and Lecture• Partners in Progress Award• Public Service Award• Distinguished Achievement Award• Special Recognition Award• ASCO Statesman Awards

All of the above awards will be presented during the Annual Meeting, with the excep-tion of the Public Service Award and the Gi-anni Bonadonna Breast Cancer Award and Lecture, which will be presented during the 2010 Breast Cancer Symposium.

Each award has its own unique history and illustrious list of past winners. The Karnofsky Award, named in honor of the outstanding research contributions of David A. Karnofsky, MD, is the oldest of the awards; the fi rst honor was conferred in 1970. Three awards — the B. J. Kennedy Award for Scientifi c Excellence in Geriatric Oncology, the Gianni Bonadonna Breast Cancer Award, and the Pediatric Oncol-ogy Award — recognize oncologists devoted to cancer care and research in specifi c patient populations. The Distinguished Achievement Award was established to recognize scientifi c accomplishments and mentorship that have benefi ted ASCO as well as the broader oncol-ogy and patient communities.

Created in 2005, the Science of Oncology Award honors an individual who has furthered the understanding of cancer through basic or translational research. The ASCO/American Cancer Society Award has existed since 1993; the award winner, selected by ASCO, is an oncologist who has exerted a signifi cant effort on behalf of cancer prevention and control research or practice. The Special Recognition

Award honors those who have made major contributions in areas of clinical oncology, cancer research, clinical trials, reimbursement, and patient advocacy activities, and it recog-nizes outstanding long-term service to ASCO and to clinical oncology. The Partners in Prog-ress Award honors valuable contributions in cancer awareness and public advocacy. The Public Service Award recognizes a person in-volved in legislative, political action, or com-munity service activities that affect public awareness about cancer, its causes, cures, or treatment, or activities that result in additional support either legislatively or fi scally for the fi eld of cancer research, treatment, prevention, or care. The ASCO Statesman Awards salute

members with a record of at least 20 years of voluntary service to the Society.

In addition to the specifi c set of criteria for each award, leading candidates are those who have major accomplishments in their fi elds, are broadly respected and admired for their professional achievements and personal at-tributes, and exhibit outstanding leadership qualities. The Special Awards Selection Com-mittee also considers each candidate’s record of publications, recognition by peers, invita-tions to lecture, implementation of success-ful programs, mentorship, and reputation for clinical excellence.

Eighty-nine individuals were nominated by their peers for the 2010 awards (States-

man Award candidates are eligible based on their service rather than nominated). After the nominations were collected and the can-didates had been reviewed for eligibility, the Committee conducted a preliminary vote to pare the pool down to a few leading candi-dates for each award, discussed each candi-date on this fi nal list, and held a fi nal vote to determine a winner.

Winners will be presented with their awards and deliver their accompanying lectures in sessions throughout the Annual Meeting (see sidebar). ASCO encourages all attendees to take the opportunity to learn about the con-tributions and dedication of these world-class scientists, clinicians, and patient advocates.

2010 ASCO Special Awards Recognize Oncology Trailblazers, Society Leaders

ASCO encourages all attendees to join the Society in honoring the Special Award win-ners. These recipients of ASCO’s highest, most prestigious awards collectively repre-sent signifi cant strides in cancer treatment and leadership in the oncology community.

David A. Karnofsky Memorial Award and Lecture honoringDaniel D. Von Hoff, MD, FACP Special SessionSaturday, June 5, 9:30 AM – 12:00 PMN Hall B1For more on Dr. Von Hoff’s career and contribu-tions to oncology, see his profi le on page 1B in today’s issue of ASCO Daily News, Section B.

Science of Oncology Award and Lecture honoringFrank McCormick, PhDPlenary SessionSunday, June 6, 1:00 PM – 4:00 PMN Hall B1For more on Dr. McCormick’s career and con-tributions to oncology, see his profi le on page 1C in today’s issue of ASCO Daily News, Section C.

ASCO-American Cancer Society Award and Lecture honoringJoseph V. Simone, MDMonday, June 7, 9:45 AM – 11:00 AMS100bFor more on Dr. Simone’s career and contribu-tions to oncology, see his profi le on page 1B in the Sunday issue of ASCO Daily News, Section B.

Gianni Bonadonna Breast Cancer Award and Lecture honoringNancy E. Davidson, MDTo be presented at the 2010 Breast Cancer SymposiumFor more on Dr. Davidson’s career, see her profi le on page 1B in today’s issue.

B. J. Kennedy Award and Lecture for Scientifi c Excellence in Geriatric Oncology honoringHarvey Jay Cohen, MDSunday, June 6, 4:45 PM – 6:00 PM, S100aFor more on Dr. Cohen’s career, see his profi le on page 1C in the Sunday issue of ASCO Daily News, Section C.

Pediatric Oncology Award and Lecture honoringSharon B. Murphy, MDSaturday, June 5, 3:00 PM – 4:15 PM, S504For more on Dr. Murphy’s career, see her pro-fi le on page 1B in the Monday issue of ASCO Daily News, Section B.

Partners in Progress Award honoringEllen V. Sigal, PhDHighlights of the Day IIMonday, June 7, 7:30 AM – 9:00 AME Hall D1For more on Dr. Sigal’s career, see her profi le on page 1C in the Sunday issue of ASCO Daily News, Section C.

Public Service Award honoringThe Honorable Kay Bailey HutchisonU.S. SenatorPresented at a private event

The following awards were presented during a private event on Friday, June 4:

Distinguished Achievement Award honoringEli Glatstein, MDFor more on Dr. Glatstein’s career and contri-butions to oncology, see his profi le on page 1C in the Monday issue of ASCO Daily News, Section C.

Special Recognition Award honoringPatrick J. Loehrer Sr., MDFor more o n Dr. Loehrer’s career and contri-butions to oncology, see his profi le on page 1C in the Monday issue of ASCO Daily News, Section C.

ASCO Statesman Awards honoringLaurence H. Baker, DO; Edward P. Balaban, DO; C. D. Blanke, MD; Howard A. Burris, III, MD; John V. Cox, DO; Robert Dreicer, MD; Stephen B. Edge, MD; Alexander M. Eggermont, MD, PhD; Charles M. Haskell, MD; Maha Hussain, MD; Mark G. Kris, MD; Theodore S. Lawrence, MD, PhD; Gary H. Lyman, MD; Gregory A. Masters, MD, FACP; Therese M. Mulvey, MD; Olufunmilayo I. Olopade, MBBS, FACP; Bruce A. Peterson, MD; William T. Purcell, MD; Derek Raghavan, MD, PhD; Gregory H. Reaman, MD; Mack Roach, III, MD; Bruce J. Roth, MD; Mace L. Rothenberg, MD; Charles A. Schiffer, MD; Branimir I. Sikic, MD; Margaret A. Tempero, MD; Linda T. Vahdat, MD; Antonio C. Wolff, MD, FACP

2010 Special Award Recipients

ASCO TV features replays of key ses-sions from the 2010 Annual Meeting, messages from ASCO leadership, and

information on important ASCO initiatives. Attendees can watch ASCO TV in select Chi-cago hotels, on all shuttle busses, and in the following areas throughout McCormick Place:• Arie Crown Theater, East Building• Grand Concourse Lobby, North Building• S103 Lobby, South Building• Food Court, Oncology Professionals Hall

Today’s ASCO TV line-up is listed at right.

Each subsequent issue of ASCO Daily News will contain a schedule of ASCO TV programming.

• 7:00 AM – 10:00 AM: Newscast with ASCO State of the Society Address; CNN

• 10:00 AM – 12:00 PM: Replay of ASCO/ASH Joint Session

• 12:00 PM – 2:00 PM: Newscast Featuring Oncology Professionals Hall; CNN

• 2:00 PM – 4:00 PM: Replay of Opening Session/Presidential Address

• 4:00 PM – 6:00 PM: Newscast featuring ASCO’s patient website, Cancer.Net; CNN

ASCO TV Offers Informative Updates, Exclusive Newscasts

SATURDAY, JUNE 5, 2010 • ASCO Daily News • 3A

mTOR

Worldwide Initiative to Develop Everolimus

THE

PR GRAMWIDE TMBOLERO

Breast cancer trials of OraL EveROlimus

BOLEROBreast cancer trials of OraL EveROlimus

BOLERO-1

BOLERO-2

BOLERO-3

Three Phase III Studies of Everolimus*in HER2+ or ER+ Breast Cancer

Now Enrolling

All of the BOLERO studies are currently enrolling. To learn more about eligibility and patient enrollment, visit www.thewideprogram.com.

* These are investigational studies; efficacy and safety have not been established for these uses. There is no guarantee that everolimus will become commercially available for these indications.

Novartis Oncology is conductingthe BOLERO program to studyeverolimus combination therapyin various breast cancer settings.

In previously untreated HER2+ locally advanced or metastatic breast cancer

In postmenopausal women with ER+ locally advanced or metastatic breast cancer that is refractory to letrozole or anastrozole

In HER2+ locally advanced or metastatic breast cancer previously treated with taxanes and resistant to trastuzumab

Novartis Pharma AG C-RAD-100015 Novartis Pharmaceuticals CorporationCH-4002 Basel, Switzerland © Novartis 2010 February 2010 GCT7428 East Hanover, NJ 07936

By Monica Morrow, MDEditor, ASCO Daily News

Welcome to Chicago and the 2010 ASCO Annual Meeting. The 2010 Meeting will feature several new

initiatives and programs that focus on the Annual Meeting theme, “Advancing Quality though Innovation.” One of these, the Trials in Progress Poster Session, will facilitate aware-ness and dialogue about open, ongoing clini-cal trials. This session is designed to encourage discussion of new clinical research opportuni-ties and allow an exchange of ideas on clinical trial design while allowing Meeting attendees an insider look into ongoing, potentially prac-tice-changing research (See the article on page 4A of this section of ASCO Daily News for more information about this new session type). Also stemming from the theme of innovation, the Annual Meeting planners and ASCO leader-ship have worked to enhance attendee–faculty interaction through the use of Internet-based, social networking technology during this af-ternoon’s Education Session “Management of Side Effects of the Treatment of Colorectal Cancer,” in which attendees can send ques-tions directly to faculty in real-time using text, e-mail, or Twitter (See the article on page 8A of this section of ASCO Daily News for more infor-mation about this interactive session type).

As refl ected in this year’s Annual Meeting theme, quality continues to be an integral part of cancer care. In an effort to highlight ASCO’s efforts in this area, the Quality Oncol-ogy Practice (QOPI®) Certifi cation Program, which was launched in January 2010, will be featured at ASCO Central (Booth #7004) in the Oncology Professionals Hall (formerly the Exhibit Hall). The program is intended to promote excellence in cancer care by pro-viding a 3-year certifi cation for outpatient hematology–oncology practices that meet the rigorous QOPI® standards.

Throughout this and subsequent issues of ASCO Daily News, you will fi nd discussions that highlight how ASCO is working to ad-vance quality through innovation, as well as articles on the most signifi cant scientifi c data being presented during the Meeting. Again this year, we will feature a series of invited ed-itorial commentaries on issues of interest to oncologists from all disciplines. These Expert Editorials appear in each day of the paper and focus on such topics as ASCO’s development of provisional clinical opinions (PCOs), the fi nancial concerns facing patients undergoing cancer treatment, and the use of electronic health records.

Every year, the award lectures are a high-light of the Annual Meeting, most notably the David A. Karnofsky Memorial Award, the ASCO/American Cancer Society Award, the B. J. Kennedy Award for Scientifi c Excellence in Geriatric Oncology, the Pediatric Oncology

Award, and the Science of Oncol-ogy Award. Nomi-nations for these awards were made by the Special Awards Selection Committee, and the recipients are individuals who have made semi-nal contributions

to their fi elds. Award lectures offer Meeting at-tendees an opportunity to hear how scientifi c breakthroughs considered standard practice today came into being, as well as the chance to

learn of new and exciting plans for the future of oncology. ASCO Daily News features pro-fi les of each award recipient throughout Sec-tions B and C — including awards for which no lecture is given, such as the Distinguished Achievement Award — in addition to cover-age of the scientifi c context of select lectures in Section A.

In an effort to be as comprehensive and timely in our Meeting coverage as possible, ASCO Daily News will post articles to the An-nual Meeting website (http://chicago2010.asco.org) in advance of their appearance in print. You also will fi nd select material from Sections B and C online, organized by day. Articles will be posted to the Annual Meeting website each morning to coincide with the on-site release of the printed product throughout McCormick Place; select articles on abstract

presentations that offer exceptionally robust data will be posted the evening before their re-lease in the print version of the paper. A daily e-mail, the ASCO Daily News Digest, will be sent each morning and will include brief clips from ASCO’s Virtual Meeting. These print and online offerings are all designed to further en-hance the attendee experience.

On behalf of myself, Associate Editor John Sweetenham, MD, FRCP, and the entire ASCO Daily News staff, I’d like to welcome you to the 2010 Annual Meeting and encour-age you to make full use of this publication. As always, ASCO Daily News seeks feedback and welcomes suggestions from readers by e-mail at ascodailynews@asco.org. I hope you enjoy your time in Chicago and that you fi nd your Meeting experience meaningful and educational.

Editor’s Welcome

Monica Morrow, MD

Illinois Governor Declares June “Oncology Month”

In conjunction with the 2010 ASCO Annual Meeting, Illinois Governor Pat Quinn has issued an offi cial proclama-

tion to declare June “Oncology Month” in recognition of the dedicated health care pro-fessionals who treat people with cancer.

4A • ASCO Daily News • SATURDAY, JUNE 5, 2010

One of the challenges facing oncolo-gists and oncology care professionals is keeping track of participation in

educational meetings and courses. To address this challenge, ASCO is pleased to announce the ASCO University™ Registrar’s Offi ce, which is now available to all oncology profes-sionals who participate in continuing educa-tion activities. This new service offers users a convenient place to view and track their meet-ing and continuing medical education (CME) credit history.

Participants are able to access information on ASCO educational activities by visiting uni-versity.asco.org/registrar and logging on with an ASCO member or guest account user. Par-ticipants can download a CME Certifi cate (for MDs and DOs), a Certifi cate of Participation (for non-physicians), a Certifi cate of Completion (for ASCO University courses), or a Certifi cate of Attendance (for meetings) at any time. In addition, users may input activity information for non-ASCO activities and upload certifi cates to have a record of all continuing education courses in one convenient place. In this easily accessible site, users can maintain a personal-ized portfolio of all available CME-accredited activities and oncologists can download an activity transcript annually to support re-licensure documentation requirements.

The Registrar’s Offi ce offers a variety of fea-tures to help oncology professionals manage

their education records. Site functionality al-lows users to browse and search their port-folio. It also offers a CME credit calculator which allows oncologists to see, at a glance, how many CME credits they have accumu-lated. In addition, the Registrar’s Offi ce is linked with a new online evaluation site which supports all ASCO meetings as well as prod-ucts such as ASCO-SEP®, the Society’s self-

evaluation publication. Electronic certifi cates will be available immediately upon submis-sion of the online evaluation, a marked im-provement from the paper evaluation process that could take up to 8 weeks to complete. Annual Meeting attendees will have instant access to their meeting certifi cate once they submit the evaluation located at chicago2010.asco.org or university.asco.org/registrar.

ASCO is proud to offer this new resource to members and non-members alike, and Society leaders are eager to see the benefi ts this service will provide for health care pro-fessionals. “The new Registrar’s Offi ce pro-vides an important and valuable service to oncology professionals that take part in our educational activities. We look forward to hearing from participants about their expe-rience with the site,” Lucille A. Leong, MD, Chair of ASCO’s CME Subcommittee, told ASCO Daily News. Comments and questions about this new feature may be directed to cme@asco.org.

The Trials in Progress Poster Session is a new scientifi c session at the Annual Meeting designed to facili-

tate awareness of open, ongoing clinical trials. The Trials in Progress Poster Ses-sion will be held on Monday, June 7, from 8:00 AM to 12:00 PM in Hall A2, South Building. This premiere session encour-ages discussion of new clinical research, promotes the exchange of ideas on clini-cal trial design, and allows Meeting at-tendees an inside look into potentially practice-changing research. This year, more than 200 abstracts will be presented and discussed; however, presentations of trial results will not take place at the Tri-als in Progress Poster Session. Meeting at-tendees are encouraged to consult either

the Meeting Program or the online Meet-ing Program (meetingplanner.asco.org)

for a full listing of the abstract titles that will be displayed at this event.

ASCO University’s™ New Registrar’s Offi ce Provides Centralized Location for Tracking Meeting Participation, CME Credit History

New Session Type Fosters Discussion of Ongoing Trial Research

VELCADE CRs Resulted in More Durable Responses

0 10 11 12 159875421Time (Months)

3 6 13 14 16

All responders(CR+CRu+PR)

(95% CI, 5.4-13.8)(n=48)

9.3

MEDIAN DURATION OF RESPONSE IN PINNACLE† TRIAL (n=48/155)

Complete responders

(CR+CRu)(95% CI, 13.4-15.4) (n=12)

15.4

* Subject to federal and state restrictions. EPOCRATES Rx Pro is a registered trademark of Epocrates, Inc. in the United States and other countries. All other trademarks referenced are those of their respective owners.

† PINNACLE, a single-arm, multicenter, phase 2 trial (N=155) evaluating the effi cacy and safety of VELCADE in mantle cell lymphoma (MCL) patients who have received at least 1 prior therapy.

VISIT BOOTH 10043 AT ASCOFOR A COMPLIMENTARY

3-MONTH SUBSCRIPTION TO EPOCRATES RX PRO®*

VELCADE Warnings, Precautions, and Adverse EventsVELCADE is contraindicated where hypersensitivity to bortezomib, boron, or mannitol exists. Warnings and Precautions for VELCADE include: advising women to avoid pregnancy and breastfeeding; peripheral neuropathy, sometimes severe may occur—manage with dose modifi cations or discontinuation and carefully consider risk/benefi t in pre-existing severe neuropathy; hypotension may occur, use caution with patients on antihypertensives, history of syncope, dehydration; closely monitor patients with risk factors for or existing heart disease; acute diffuse infi ltrative pulmonary disease has been reported; nausea, diarrhea, constipation, and vomiting may require symptomatic treatment; regular monitoring of blood counts throughout treatment for thrombocytopenia or neutropenia. Tumor Lysis Syndrome, Reversible Posterior Leukoencephalopathy Syndrome, and acute hepatic failure have been reported. In patients with moderate or severe hepatic impairment use a lower starting dose. In addition, patients with diabetes may require close monitoring of blood glucose and antidiabetic medication. Most commonly reported adverse reactions (incidence ≥30%) in clinical studies include asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders, anorexia and decreased appetite, neutropenia, neuralgia, leukopenia, and anemia. Other adverse reactions, including serious adverse reactions, have been reported.

Please see Brief Summary for VELCADE on next page.VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.

▼ VELCADE® (bortezomib) is the only FDA-approved therapy for patients with relapsed MCL

▼ VELCADE delivers a 31% overall response rate, with 8% CR (CR+CRu)

▼ Responding patients received a median of 8 cycles of treatment with VELCADE

▼ VELCADE has a well-characterized safety profi le

For Patient Assistance Information or Reimbursement Assistance call 1-866-VELCADE (835-2233), OPTION 2, or visit www.VELCADE.com.

6A • ASCO Daily News • SATURDAY, JUNE 5, 2010

VELCADE, MILLENNIUM and are registered trademarks of Millennium Pharmaceuticals, Inc.Other trademarks are property of their respective owners.

Millennium Pharmaceuticals, Inc., The Takeda Oncology Company. Cambridge, MA 02139Copyright © 2010, Millennium Pharmaceuticals, Inc.

Please see full Prescribing Information for VELCADE atwww.VELCADE.com.

INDICATIONS:

VELCADE® (bortezomib) for Injection is indicated for the treatment of patients with multiple myeloma.VELCADE® (bortezomib) for Injection is indicated for the treatment of patients with mantle cell lymphomawho have received at least 1 prior therapy.

CONTRAINDICATIONS:

VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.

WARNINGS AND PRECAUTIONS:

VELCADE should be administered under the supervision of a physician experienced in the use ofantineoplastic therapy. Complete blood counts (CBC) should be monitored frequently during treatment withVELCADE.

Pregnancy Category D: Women of childbearing potential should avoid becoming pregnant while beingtreated with VELCADE. Bortezomib administered to rabbits during organogenesis at a dose approximately0.5 times the clinical dose of 1.3 mg/m2 based on body surface area caused post-implantation loss and adecreased number of live fetuses.

Peripheral Neuropathy: VELCADE treatment causes a peripheral neuropathy that is predominantly sensory.However, cases of severe sensory and motor peripheral neuropathy have been reported. Patients withpre-existing symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheralneuropathy may experience worsening peripheral neuropathy (including ≥Grade 3) during treatment withVELCADE. Patients should be monitored for symptoms of neuropathy, such as a burning sensation,hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain or weakness. Patients experiencingnew or worsening peripheral neuropathy may require change in the dose and schedule of VELCADE.Following dose adjustments, improvement in or resolution of peripheral neuropathy was reported in 51%of patients with ≥Grade 2 peripheral neuropathy in the relapsed multiple myeloma study. Improvement inor resolution of peripheral neuropathy was reported in 73% of patients who discontinued due to Grade 2neuropathy or who had ≥Grade 3 peripheral neuropathy in the phase 2 multiple myeloma studies. Thelong-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma.

Hypotension: The incidence of hypotension (postural, orthostatic, and hypotension NOS) was 13%. Theseevents are observed throughout therapy. Caution should be used when treating patients with a history ofsyncope, patients receiving medications known to be associated with hypotension, and patients who aredehydrated. Management of orthostatic/postural hypotension may include adjustment of antihypertensivemedications, hydration, and administration of mineralocorticoids and/or sympathomimetics.

Cardiac Disorders: Acute development or exacerbation of congestive heart failure and new onset ofdecreased left ventricular ejection fraction have been reported, including reports in patients with no riskfactors for decreased left ventricular ejection fraction. Patients with risk factors for, or existing heart diseaseshould be closely monitored. In the relapsed multiple myeloma study, the incidence of any treatment-emergent cardiac disorder was 15% and 13% in the VELCADE and dexamethasone groups, respectively.The incidence of heart failure events (acute pulmonary edema, cardiac failure, congestive cardiac failure,cardiogenic shock, pulmonary edema) was similar in the VELCADE and dexamethasone groups, 5% and4%, respectively. There have been isolated cases of QT-interval prolongation in clinical studies; causalityhas not been established.

Pulmonary Disorders: There have been reports of acute diffuse infiltrative pulmonary disease of unknownetiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory DistressSyndrome (ARDS) in patients receiving VELCADE. Some of these events have been fatal. In a clinical trial,the first two patients given high-dose cytarabine (2 g/m2 per day) by continuous infusion with daunorubicinand VELCADE for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy. Therehave been reports of pulmonary hypertension associated with VELCADE administration in the absence ofleft heart failure or significant pulmonary disease. In the event of new or worsening cardiopulmonarysymptoms, a prompt comprehensive diagnostic evaluation should be conducted.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): There have been reports of RPLS in patientsreceiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure,hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances.Brain imaging, preferably MRI (Magnetic Resonance Imaging), is used to confirm the diagnosis. In patientsdeveloping RPLS, discontinue VELCADE. The safety of reinitiating VELCADE therapy in patients previouslyexperiencing RPLS is not known.

Gastrointestinal Adverse Events: VELCADE treatment can cause nausea, diarrhea, constipation, andvomiting sometimes requiring use of antiemetic and antidiarrheal medications. Ileus can occur. Fluid andelectrolyte replacement should be administered to prevent dehydration.

Thrombocytopenia/Neutropenia: VELCADE is associated with thrombocytopenia and neutropenia thatfollow a cyclical pattern with nadirs occurring following the last dose of each cycle and typically recoveringprior to initiation of the subsequent cycle. The cyclical pattern of platelet and neutrophil decreases andrecovery remained consistent over the 8 cycles of twice weekly dosing, and there was no evidence ofcumulative thrombocytopenia or neutropenia. The mean platelet count nadir measured was approximately40% of baseline. The severity of thrombocytopenia was related to pretreatment platelet count. In therelapsed multiple myeloma study, the incidence of significant bleeding events (≥Grade 3) was similar onboth the VELCADE (4%) and dexamethasone (5%) arms. Platelet counts should be monitored prior to eachdose of VELCADE. Patients experiencing thrombocytopenia may require change in the dose and scheduleof VELCADE. There have been reports of gastrointestinal and intracerebral hemorrhage in association withVELCADE. Transfusions may be considered. The incidence of febrile neutropenia was <1%.

Tumor Lysis Syndrome: Because VELCADE is a cytotoxic agent and can rapidly kill malignant cells, thecomplications of tumor lysis syndrome may occur. Patients at risk of tumor lysis syndrome are those with hightumor burden prior to treatment. These patients should be monitored closely and appropriateprecautions taken.

Hepatic Events: Cases of acute liver failure have been reported in patients receiving multiple concomitantmedications and with serious underlying medical conditions. Other reported hepatic events includeincreases in liver enzymes, hyperbilirubinemia, and hepatitis. Such changes may be reversible upondiscontinuation of VELCADE. There is limited re-challenge information in these patients.

Patients with Hepatic Impairment: VELCADE is metabolized by liver enzymes. VELCADE exposure isincreased in patients with moderate or severe hepatic impairment. These patients should be treated withVELCADE at reduced starting doses and closely monitored for toxicities.

ADVERSE EVENT DATA:

Safety data from phase 2 and 3 studies of single-agent VELCADE 1.3 mg/m2/dose twice weekly for 2weeks followed by a 10-day rest period in 1163 patients with previously treated multiple myeloma(N=1008, not including the phase 3, VELCADE plus DOXIL® [doxorubicin HCI liposome injection] study) andpreviously treated mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, thesafety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma.

In the integrated analysis, the most commonly reported adverse events were asthenic conditions (includingfatigue, malaise, and weakness); (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheralneuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated); (39%),thrombocytopenia and appetite decreased (including anorexia); (each 36%), pyrexia (34%), vomiting (33%),anemia (29%), edema (23%), headache, paresthesia and dysesthesia (each 22%), dyspnea (21%), coughand insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo);(each 17%), pain in limb and abdominal pain (each 15%), bone pain (14%), back pain and hypotension(each 13%), herpes zoster, nasopharyngitis, upper respiratory tract infection, myalgia and pneumonia(each 12%), muscle cramps (11%), and dehydration and anxiety (each 10%). Twenty percent (20%) ofpatients experienced at least 1 episode of ≥Grade 4 toxicity, most commonly thrombocytopenia (5%) andneutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies.The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%),and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

In the phase 3 VELCADE + melphalan and prednisone study, the safety profile of VELCADE in combination withmelphalan/prednisone is consistent with the known safety profiles of both VELCADE and melphalan/prednisone.The most commonly reported adverse events in this study (VELCADE+melphalan/prednisone vsmelphalan/prednisone) were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea(48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%),constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs 16%),pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10%),asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%),rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%),dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain(14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%),hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension(12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), bone pain (11% vs 10%),arthralgia (11% vs 15%) and pruritus (10% vs 5%).

DRUG INTERACTIONS:

Co-administration of ketoconazole, a potent CYP3A inhibitor, increased the exposure of bortezomib.Therefore, patients should be closely monitored when given bortezomib in combination with potent CYP3A4inhibitors (e.g. ketoconazole, ritonavir). Co-administration of melphalan-prednisone increased the exposureof bortezomib. However, this increase is unlikely to be clinically relevant. Co-administration of omeprazole,a potent inhibitor of CYP2C19, had no effect on the exposure of bortezomib. Patients who are concomitantlyreceiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closelymonitored for either toxicities or reduced efficacy.

USE IN SPECIFIC POPULATIONS:

Nursing Mothers: It is not known whether bortezomib is excreted in human milk. Because many drugs areexcreted in human milk and because of the potential for serious adverse reactions in nursing infants fromVELCADE, a decision should be made whether to discontinue nursing or to discontinue the drug, taking intoaccount the importance of the drug to the mother.

Pediatric Use: The safety and effectiveness of VELCADE in children has not been established.

Geriatric Use: No overall differences in safety or effectiveness were observed between patients ≥age 65 andyounger patients receiving VELCADE; but greater sensitivity of some older individuals cannot be ruled out.

Patients with Renal Impairment: The pharmacokinetics of VELCADE are not influenced by the degree of renalimpairment. Therefore, dosing adjustments of VELCADE are not necessary for patients with renal insufficiency.Since dialysis may reduce VELCADE concentrations, the drug should be administered after the dialysisprocedure. For information concerning dosing of melphalan in patients with renal impairment, seemanufacturer's prescribing information.

Patients with Hepatic Impairment: The exposure of VELCADE is increased in patients with moderate andsevere hepatic impairment. Starting dose should be reduced in those patients.

Patients with Diabetes: During clinical trials, hypoglycemia and hyperglycemia were reported in diabeticpatients receiving oral hypoglycemics. Patients on oral antidiabetic agents receiving VELCADEtreatment may require close monitoring of their blood glucose levels and adjustment of the dose of theirantidiabetic medication.

Brief Summary

All rights reserved. Printed in USA V1284 03/10

ASCO has released a provisional clinical opinion (PCO) on the use of screening for Hepatitis B virus

(HBV) infection for patients who are about to undergo chemotherapy for the treatment of malignant disease. A PCO is a rapid-response mechanism that offers timely clinical direc-tion to ASCO’s membership following publi-cation or presentation of potentially practice-changing data from major studies.

The PCO, “Chronic Hepatitis B Infection Screening in Patients Receiving Cytotoxic Che-motherapy for Treatment of Malignant Diseas-

es,” addresses the Centers for Disease Control and Prevention (CDC) guideline update that recommended all patients who are about to re-ceive chemotherapy be screened for HBV.

“This new PCO is a useful tool for practicing oncologists who are facing the decision of whether and how to test their patients about to undergo chemotherapy for Hepatitis B,” Mi-chael Neuss, MD, Clinical Practice Committee Chair, said in an interview with ASCO Daily News. “Based on the best available evidence, it provides practical guidance on the issue of routine screening in this setting.”

The PCO recommends that some — but not all — patients with cancer are identifi ed for HBV screening if they are going to receive cytotoxic or immunosuppressive therapy as part of cancer therapy.

“This PCO refl ects expert consensus based on clinical evidence and literature available at the time they are written, and is intended to assist physicians in clinical decision-mak-ing and identify questions and settings for further research,” Sandra Wong, MD, 2009-2010 Chair of the Clinical Practice Guide-lines Committee, said.

“In the end, our research found that the evidence is insuffi cient to determine the net benefi ts and harms of routine screening for chronic HBV infection in individuals with cancer who are about to receive cytotoxic or immunosuppressive therapy or who are al-ready receiving therapy,” she said.

Below are the main points of the PCO. Full text of the PCO is available in the Journal of Clinical Oncology (JCO); a related commen-tary will also be available in the July 2010 issue of the Journal of Oncology Practice (JOP).

Provisional Clinical Opinion The evidence is insuffi cient to determine the

net benefi ts and harms of routine screening for chronic HBV infection in individuals with can-cer who are about to receive cytotoxic or im-munosuppressive therapy or who are already receiving therapy. Individuals with cancer who undergo certain cytotoxic or immunosuppres-sive therapies and have HBV infection or prior exposure to HBV may be at elevated risk of liver failure from HBV reactivation. As such, screening requires clinical judgment. Physi-cians may consider screening patients belong-ing to groups at heightened risk for chronic HBV infection or if highly immunosuppressive therapy is planned. Highly immunosuppres-sive treatments include, but are not limited to, hematopoietic cell and marrow transplan-tation and regimens including rituximab. Screening based on a high risk of prior HBV exposure or risk of reactivation due to planned therapeutic regimens should include testing for hepatitis B surface antigen (HBsAg) as a serologic marker for HBV infection. In some populations, testing for anti-hepatitis B core antigen (anti-HBc) should also be considered. There is no evidence to support serologic test-ing for antibodies to HBsAg (anti-HBs) in this context. When evidence for chronic HBV in-fection is found, pre-emptive antiviral therapy may be considered to reduce the risk of HBV reactivation, although evidence from con-trolled trials of this approach is limited.

For more information about the PCO de-velopment, see Dr. Wong’s Expert Editorial on page 2B of this issue of ASCO Daily News.

ASCO Issues Provisional Clinical Opinion on Hepatitis B Screening and Chemotherapy

Attendees are encouraged to docu-ment their participation by re-questing either a CME Certifi cate

(MD and DO) or a Certifi cate of Participa-tion to claim credits toward relicensure (for nonphysicians). Immediately after submit-ting an evaluation, users will be directed to ASCO’s Registrar’s Offi ce, where the certifi cate will be available for download-ing. These certifi cates will be accessible by entering your ASCO.org username and password at university.asco.org/registrar.

Evaluations must be submitted online at www.asco.org/cme, and will be ac-cepted until Friday, July 9, 2010; paper evaluations are no longer being accepted.

Completion of an evaluation enters attendees into a drawing to receive com-plimentary registration for the 2011 An-nual Meeting.

Onsite evaluation support is available at the Meeting Evaluation Help Desk in the Grand Concourse Lobby Saturday through Monday from 7:00 AM – 6:00 PM and Tuesday: 7:00 AM – 1:00 PM

Submit Program Evaluation Online

SATURDAY, JUNE 5, 2010 • ASCO Daily News • 7A

ResourcesContinued from Page 1A

opportunities. Notably, the hall will include the Technology and Practice Management Pavilion, featuring the latest technologies for health care professionals; the Publishers Pavilion, with oncology-related books and journals from more than 50 publishing orga-nizations; and the Career Opportunities and Other Medical Meetings Posting Boards.

New this year in the Oncology Profession-als Hall is the Networking & Connection Hub (Booth #10163), which will serve as a venue for topic-based discussions, technol-ogy demonstrations, and casual, face-to-face meetings with select ASCO leadership. Scheduled sessions within the Networking and Connection Hub include demonstrations of e-book readers and smartphone applica-tions; an introduction to ASCO’s social net-working presence on Twitter, LinkedIn, and Facebook; and an ASCO Tweet Up. The Net-working & Connection Hub is located in the back of the Oncology Professionals Hall near the Food Court (see page 12A for a comprehen-sive Networking and Connection Hub schedule).

For fellows and junior faculty who may be attending the Meeting for the fi rst time, the Education Session “How to Navigate the Annual Meeting” will provide an in-depth look on how to optimize the Annual Meeting experience. The session will take place this morning from 7:30 AM – 8:00 AM in Room S501.

Stemming from ASCO’s successful publi-cation choice program at last year’s Annual Meeting, attendees are invited to choose to receive the 2010 ASCO Educational Book and the 2010 ASCO Annual Meeting Proceedings Part I in print or on a USB drive. A quick reference guide, which includes the Annual Meeting Program Calendar of Events, also will be available on the USB to help attend-ees maximize their effi ciency at the Meeting. The content will be available online at www.asco.org/eTote2010 to all registered attendees through June 18, 2010.

In addition to the abstracts from ASCO Annual Meeting Proceedings Part I being avail-

able in print, and on USB, the fully search-able abstracts are available online at abstract.asco.org. The majority of Proceedings Part II abstracts — including Plenary, Late-break-ing, and Clinical Review Abstracts — will be

available online today at 12:00 PM EDT, with the rest being released Sunday at 12:00 PM EDT. Publish-only abstracts, which are pub-lished in conjunction with the Annual Meet-ing but are not presented, are available online at www.jco.org and www.asco.org/abstracts.

Post-Meeting Products, ServicesAfter the Meeting’s conclusion, attendees

can continue their Annual Meeting experi-ence with a Virtual Meeting subscription. Vir-tual Meeting includes video and slides from all non-ticketed educational and scientifi c sessions, as well as submitted posters. Pre-sentations are available within 24 hours of a session’s completion. Attendees can visit the ASCO Store (Booth #7004) in the Oncology Professionals Hall or the Virtual Meeting and Podcast Station, located in the North Build-

ing on Level 2.5, for more information about Virtual Meeting.

Additionally, attendees can continue learn-ing through virtual access to Clinical Prob-lems in Oncology (eCPO) Sessions from the Meeting. eCPO sessions combine case-based panel discussions with audience participa-tion, and will be available for purchase on Monday, June 7. Attendees who purchased eCPO sessions with their Annual Meeting registration will have access to the virtual ses-sions within 24 hours of their completion. Content is available on ASCO University™ (university.asco.org), ASCO’s online educa-tional platform.

For more information on all ASCO Annual Meeting resources, publications, and events, visit ASCO Central (Booth #7004) in the On-cology Professionals Hall.

Once in a while, something remarkable

happens in cancer care. One of those

moments is now a reality. The most

comprehensive and patient friendly cancer

facility in New England is here. Smilow

Cancer Hospital at Yale-New Haven.

500,000 square feet of advanced treatment

facilities. Twelve teams of specialists, each

nationally recognized for their pioneering

work in specifi c forms of cancer. The

development of an extensive range of novel

drugs and therapies, delivered directly to the

bedside. And a rooftop healing garden

where a cancer patient can refocus on life.

For thousands of patients and their families,

cancer care is not only infi nitely more

promising, it’s infi nitely easier to attain. To

learn more, visit

The future of cancer care has opened its doors.

Yale-New Haven Hospital is the primary teaching hospital of Yale School of Medicine and is ranked among the nation’s best hospitals by U.S.News & World Report. Smilow Cancer Hospital at Yale-New Haven works in partnership with Yale Cancer Center – A National Cancer Institute-designated Comprehensive Cancer Center.

Annual Meeting attendees can con-nect to the Internet at several stations throughout the convention center:• 28 stations in the Grand Concourse• 9 stations in the Oncology

Professionals Hall• 6 stations near Gate 2, near the

S100 meeting rooms• 6 stations near Connie’s/McDonald’s

(North Building, Level 2)• 6 stations in the D2 Food Service area

ePosters Enhance Annual Meeting Experience for Attendees

Back for the second time, ePosters allow attendees the opportu-nity to view poster presentations

electronically throughout McCormick Place for the duration of the 2010 An-nual Meeting. Visit the ePoster Stations in the Oncology Professionals Hall or stop by the Virtual Meeting Replay Station in the North Building, Level 2.5 to take advantage of this interactive electronic enhancement to this year’s Meeting. ePosters allow Meeting attendees to view electronic posters before they are avail-able on Virtual Meeting and offer a more detailed look at the poster with the “Pan & Zoom” feature. Attendees also are able to e-mail the poster presenter directly with questions or comments about the data.

8A • ASCO Daily News • SATURDAY, JUNE 5, 2010

Dedicationto the development of new therapiesfor cancer patients and their families

Knowledgeand expertise to be on the forefront ofnovel, innovative medical advances

Passionfor everything we do atOnyx Pharmaceuticals

©2010 Onyx Pharmaceuticals, Emeryville, CA0410.ONYX.011 4/10 Printed in USA

2100 Powell Street, Emeryville, CA 94608 USAChanging the Way Cancer Is Treatedis a trademark of Onyx Pharmaceuticals, Inc.

TAKE AIM AT CANCERVisit booth #16005 and play the MOA challenge gameYour participation will support donations to charitable organizations

The 2010 ASCO Annual Meeting will feature the Education Session, “Management of Side Effects of the

Treatment of Colorectal Cancer,” which will serve as a pilot program encouraging attendees to send questions to participat-ing faculty by text, e-mail, or Twitter. The Session is chaired by Howard S. Hochster, MD, who will also participate as a speaker; Bruce Minsky, MD, and Mario Lacouture, MD, will also serve as faculty during the Session.

During the Session, attendees will have multiple means of submitting a question for consideration by the panel of speakers. Mi-crophones will be available throughout the

room for those who wish to ask a question orally. Questions also may be sent by texting the word “ASCO” along with a question to 22333. Attendees with Twitter accounts can tweet a question to @poll plus the keyword “ASCO”. Additionally, questions may be submitted online at http://poll4.com using the keyword “tumor”.

Session faculty and the Meeting planners are very excited about the introduction of this new technology and hope it makes the Annual Meeting a more interactive learning experience for the attendees. Dr. Hochster said, “Most of us do not have the opportu-nity to ask questions at these sessions. By utilizing email, texting, or tweets attendees

will interact with the panelists in real time and pose the questions on their minds re-lating to management of colorectal cancer treatment side effects.”

Feedback from attendees on the value of using text messaging and Twitter to increase session interactivity is welcome. Attendees are encouraged to share their comments and reactions to the education session on their Annual Meeting evaluation (www.asco.org/cme).

“Management of Side Effects of the Treat-ment of Colorectal Cancer” is open to all attendees and will take place this afternoon from 1:15 PM to 2:30 PM in Room E354b; no ticket is required to attend.

Interactive Session Utilizes Technology, Social Networking

Annual Meeting Supporters

The following is a list of supporters added after the publication of the original list appearing in Section C.

Bristol-Myers SquibbLymphoma and Plasma Cell Disorders TrackCelgene CorporatonBest of ASCO® MeetingsLeukemia, Myelodysplasia, and

Transplantation TrackLymphoma and Plasma Cell Disorders TrackCentocor Ortho Biotech Inc. Gynecologic Cancers TrackGenentech BioOncology™

Gastrointestinal (Colorectal) Cancers TrackGenitourinary Cancers TrackLung Cancer TrackLymphoma and Plasma Cell Disorders TrackProfessional Development TrackLilly USA, LLCGastrointestinal (Colorectal) Cancers TrackMerck OncologyCentral Nervous System Tumors TrackMelanoma TrackMillennium: The Takeda Oncology

CompanyProfessional Development TrackPurdue Pharma L.P. Patient and Survivor Care Track

GENERAL SUPPORTAbraxis BioScience The ASCO Cancer Foundation®

Young Investigator Award (2)American Cancer SocietyAmerican Cancer Society Award and LectureThe ASCO Cancer Foundation®

The ASCO Cancer Foundation® Career Development Award

The ASCO Cancer Foundation® Young Investigator Award

AstraZeneca Virtual MeetingsBayer Healthcare Pharmaceuticals The ASCO Cancer Foundation®

General ContributionEisai Inc.The ASCO Cancer Foundation®

General ContributionMillennium: The Takeda Oncology

CompanyThe ASCO Cancer Foundation®

Oncology Trainee Travel AwardNovartis OncologyThe ASCO Cancer Foundation®

General ContributionOnyx Pharmaceuticals, Inc. The ASCO Cancer Foundation®

General Contribution

This list refl ects commitments as of April 29, 2010.

SATURDAY, JUNE 5, 2010 • ASCO Daily News • 9A

EMEND is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Copyright © 2010 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. 21051066(4)-05/10-EME

Come see what’s happening at Merck Booth 2063.

The latest science in oncology isn’t the only advancement coming out of this year’s ASCO Annual Meeting.

A monthly publication for the cancer com-munity — The ASCO Post — is making its debut.

This newspaper-style publication, the result of a partnership between ASCO and Harborside Press, reports on the latest news in clinical cancer research, patient care, and policy. It includes timely commentary on the most important issues in the fi eld of oncology today, including health care reform, access to quality care, and cost of cancer care.

“After studying the environment, we rec-ognized the need for highly validated re-porting on need-to-know cancer research and policy news, patient care, and clinical practice issues, as well as thoughtful com-mentary from leaders in the fi eld,” ASCO CEO Allen S. Lichter, MD, said in an inter-view with ASCO Daily News. “As the profes-sional Society that promotes and advances the highest quality multidisciplinary cancer care, we have a unique responsibility to help our community stay current in the fast-changing world of clinical oncology.”

About the Editor-in-ChiefThe ASCO Post is overseen by Editor-in-

Chief and former ASCO President James O. Armitage, MD, of the University of Ne-braska, and an editorial advisory board of recognized leaders in oncology. Dr. Armit-age and the advisory board steer the edito-rial direction of the publication and vet the content for clinical integrity, accuracy, and merit.

“The ASCO Post will provide to each member of our Society regular and timely highlights of important clinical studies pub-lished in the Journal of Clinical Oncology and other peer-reviewed journals and presented at national and international oncology meet-

ings,” Dr. Armitage said in an interview with ASCO Daily News. “Regular columns will provide opinions on important issues af-fecting our disciplines, insights into patient care, and challenges facing academic and private practice.

“What we hope will be an entertaining feature is an ongoing ASCO forum where two members will debate controversial is-sues affecting oncology,” Dr. Armitage said. “We will then solicit the opinions of our membership and publish these as letters. The hope of all involved in this new ASCO publication is that it will make member-ship in our Society even more valuable and meaningful.”

Audience and SubscriptionsThe ASCO Post will serve a broad audience

of oncology professionals and is intended for everyone with an interest in oncology. As a benefi t of membership, the print edition is distributed to all U.S.-based ASCO members; U.S. and international ASCO members will receive complimentary online access. In ad-dition, non-ASCO member oncologists, he-matologists, and hematologist/oncologists in the United States are eligible for a compli-mentary subscription.

The ASCO Post will be published monthly in 2010, with the potential to increase pub-lication to 18 to 24 times per year after the fi rst year.

The publication is available online at www.ascopost.com and is updated frequent-ly with oncology news and information.

About the PublisherHarborside Press is a medical publish-

ing company based in Cold Spring Harbor, New York. It is responsible for the day-to-day management of The ASCO Post and its report-ing staff, which includes a team of science writers with extensive experience in oncol-ogy reporting.

Visit Booth #12063 in the Oncology Pro-fessionals Halls to receive a free copy of the inaugural issue of The ASCO Post.

The ASCO Post Debuts at 46th Annual Meeting

Annual Meeting Program Updates

Today’s EHR Didactic Sessions origi-nally scheduled from 11:00 AM – 12:00 PM (EHR Implementation: Project Man-agement Help) and 3:00 PM – 4:00 PM (EHR Selection: Tackling Your Fears) have been cancelled. Additionally, Sun-day’s EHR Didactic Sessions originally scheduled from 9:45 AM – 10:45 AM (EHR Selection: Tackling Your Fears) and 4:45 PM – 5:45 PM (EHR Imple-mentation: Project Management Help) have also been cancelled.

Attendees with EHR-related questions may visit the EHR Lab (Booth #16087) in the Oncology Professionals Hall.

Additionally, an update has been made to the faculty for this morning’s Clinical Science Symposium, “Genetic and Mo-lecular Predictors in Genitourinary Malig-nancies” (8:00 AM – 9:30 AM; E Hall D2):

Discussant: Mark A. Rubin, MDWeill Cornell Medical College8:30 AM (Abstracts 4500-4501)

10A • ASCO Daily News • SATURDAY, JUNE 5, 2010

The ASCO Cancer Foundation® is pleased to announce Isabelle Bed-rosian, MD, FACS, as the recipient

of the 2010 Advanced Clinical Research Award (ACRA) in Breast Cancer for her re-search, “Oncogene activation of DNA dam-age response as a biomarker of breast cancer risk and possible target for prevention.” Dr. Bedrosian is Assistant Professor in the De-partment of Surgical Oncology, Division of Surgery, at The University of Texas M. D. An-derson Cancer Center.

The ACRA in Breast Cancer is a 3-year $450,000 grant designed to fund investiga-tors who are committed to clinical cancer research and who wish to conduct original research not currently funded. Her pro-posal focuses on the DNA damage response (DDR) pathway, which, in recent years, has been proposed as an important barrier to cancer prevention as a result of a variety of different cancer-causing genes, Dr. Bedro-sian explained in an interview with ASCO Daily News.

“Our ability to predict who is truly at risk for developing breast cancer is limited,” she said. “I believe that examining a wom-an’s breast tissue for molecular evidence of cancerous change offers an opportunity to be more precise and more personalized in breast cancer risk prediction. I hypoth-esize that we can take this idea to its earli-est clinical application and explore whether DNA damage pathway biomarkers can serve as the early molecular predictors of future breast cancer risk.”

To test this, Dr. Bedrosian and her team will conduct a nested case-control study using volunteers from the Love/Avon Army of Women to determine the association be-tween DDR pathway biomarkers in normal

breast tissue and the develop-ment of sporadic invasive breast cancer. The data from the study, along with epide-miologic risk fac-tors, will be used to construct a preliminary risk-prediction model

and compare its discriminatory power with that of the widely used Gail Model risk as-sessment tool.

With the use of laboratory models, Dr. Bedrosian and her team will also investigate the effect of oncogene-induced DNA damage on the transformation of normal mammary epithelial cells; the role of DNA repair in miti-gating this risk of malignant transformation also will be explored.

Lastly, the research team will attempt to uncover whether the presence of oncogene-induced DNA damage in mammary epithelial cells sensitizes these cells to therapy-inhibit-ing DNA repair pathways, providing preclini-cal data for a potentially novel means of tar-geted breast cancer chemoprevention.

Dr. Bedorosian told ASCO Daily News she was “greatly honored” to have been selected for this award, especially “given the competi-tive nature of this award and the fact that I had colleagues whom I greatly respect who were also in the running.”

When asked what drove her to pursue a career in cancer research, specifi cally breast cancer research, she explained the personal connection she feels to the disease. “I know my family members have benefi ted from the research that has come before, so I un-

derstand how important research is in mov-ing ahead [the process of] cancer care and achieving cancer cures,” she said.

The second factor that guided Dr. Bedro-sian toward breast cancer research was her desire to meet the intellectual challenge of trying to fi nd new treatments for patients fac-ing a cancer diagnosis. “I was most drawn to the questions that remain unanswered in this fi eld and also because of the great motivation and dedication of [these] patients to partner with investigators in conducting research studies,” she told ASCO Daily News.

Dr. Bedrosian believes The ASCO Cancer Foundation® Grants Program is invaluable since many funding mechanisms shy away from ideas that do not have an established track record. “Grants like the Advanced Clinical Research Award are vital to allowing investigators with new and different ideas to move ahead with their research programs. This is clearly a prestigious award and gives credibility and visibility to the work I am en-gaged in,” she added.

The 2010 Advanced Clinical Research Award in Breast Cancer is generously sup-ported by T he Breast Cancer Research Foun-dation (BCRF). The grant totals $450,000 and is paid in three annual increments of $150,000 of each year of the grant term. Grant funds are directed to the sponsoring institution and are used toward salary sup-port, supplies, equipment, and travel that are necessary for the continued pursuit of the recipient’s research project. Since 2004, The ASCO Cancer Foundation and BCRF have been collaborating to support innovative clinical and translational projects to advance breast cancer research, funding innovative research proposals for fi ve previous ACRA in Breast Cancer recipients.

Dr. Isabelle Bedrosian Honored with Advanced Clinical Research Award in Breast Cancer for Distinguished Research Proposal

Isabelle Bedrosian, MD, FACS

In April 2010, ASCO was among the fi rst organizations to sign the Council of Medical Specialty Societies (CMSS)

Code of Conduct for Interactions with Companies. The voluntary code provides detailed guidance to medical specialty so-cieties on appropriate interactions with for-profi t companies in the health care sector and is designed to ensure that soci-eties’ interactions with companies are in-dependent and transparent and advance medical care for the benefi t of patients.

Though most societies already have their own rigorous confl ict of interest policies in place, there was not a single set of ethical standards for society–in-dustry interactions. This changed when CMSS, a nonprofi t organization repre-senting more than 30 medical specialty societies, convened a Task Force of rep-resentatives from member organizations to develop a common code of ethics for industry interactions.

As a member of the CMSS Task Force, ASCO has worked with CMSS for more than a year to develop the voluntary code.

ASCO CEO Allen S. Lichter, MD, Chaired the CMSS Task Force on Profes-sionalism and Confl ict of Interest that developed the code.

“For many years, ASCO has been a lead-er in establishing and enforcing rigorous confl ict of interest policies for those who participate in our programs. We take very seriously the trust that is placed in us by physicians and patients to be authoritative, independent voices in cancer care,” Dr. Lichter said. “We are proud to be one of the fi rst signers of this code, and urge our fellow medical societies to do the same.”

The code includes seven core prin-ciples and detailed guidance on imple-mentation. The principles cover the fol-lowing key areas, among others:

Confl icts of interest: Develop and publicly post policies and procedures to disclose and manage confl icts of interest among those who participate in society activities.

Financial disclosure: Publicly dis-close donations and support received from for-profi t companies in the health sector and disclose Board members’ fi -nancial and uncompensated relation-ships with companies.

Independent program development: Develop and make publicly available policies and procedures that ensure that educational programs, advocacy posi-tions, and research grants are developed independent of industry supporters.

Independent leadership: Prohibit key society leaders (presidents, CEOs, and editors-in-chief of society journals) from having direct fi nancial relation-ships with relevant for-profi t companies in the health care sector.

The full code and the list of societies who have adopted it thus far are avail-able on the CMSS website at www.cmss.org/codeofconduct. For a summary of ASCO’s policies, visit www.asco.org/con-fl ictofi nterest.

ASCO Adopts Code for Interactions with Private Sector

Each year ASCO Daily News, the offi cial onsite daily newspaper of the ASCO Annual Meeting, provides attendees

with comprehensive, accurate, and timely Meeting coverage. Valuable logistic informa-tion, Society news, and expert perspectives on controversial and relevant topics in oncol-ogy are also available in the paper. The 2010 ASCO Daily News has this and much more to offer readers, with new articles and exclusive clips from Virtual Meeting posted online each day, expanded session coverage, and a wide range of article formats.

Each day’s issue contains three sections — with the exception of the Tuesday issue — and can be found in bins throughout McCormick Place. For the third year, a Japanese language version of the newspaper will also be avail-able for attendees. Section A contains live, in-depth coverage of select high-profi le abstract presentations and the discussions that follow. Special Sessions, such as the Presidential Ad-dress and those sessions that are jointly spon-sored by other societies, as well as coverage of lectures given by Special Award winners, also are contained in Section A.

Section B is home to several regular columns

focusing on the latest updates from the Jour-nal of Clinical Oncology (JCO) and the Journal of Oncology Practice (JOP), upcoming educational events, and the mission, history, and future di-rections of The ASCO Cancer Foundation®. Section C contains overviews of the products and services available to attendees in addition to valuable logistic information. Sections B and C both feature Expert Editorials on issues of interest to the global oncology community. ASCO’s contributions to the cancer care team are highlighted in articles that provide infor-mation on guidelines, the benefi ts of ASCO membership, and new programs for the next generation of oncologists, such as the Leader-ship Development Program. In addition, pro-fi les of Special Award recipients, such as the David A. Karnofsky Memorial Award, appear in Sections B and C each day.

In addition to the traditional print of-ferings, ASCO Daily News will be available online during and following the Meeting. A daily e-mail, the ASCO Daily News Di-gest, will be sent each morning to further enhance the attendee experience at the Annual Meeting. New this year, the ASCO Daily News Digest will feature clips from

ASCO’s Virtual Meeting, offering attendees an exclusive look into select sessions.

Please visit the Annual Meeting website (chicago2010.asco.org) each day for new con-tent from ASCO Daily News; the Virtual Meet-ing clips included as part of the daily e-mail also will be available here for attendees to view.

Pick up a copy of ASCO Daily News — in English or Japanese — each day to enhance the onsite experience and get the latest scien-tifi c highlights from the 2010 ASCO Annual Meeting.

ASCO Daily News Offers Exclusive Meeting Coverage for Attendees

We Are Here to Help You Help Your Patients – Free of Charge!

Are Your Patients Struggling to Access Your Care or Medications Due to Insurance Denials?

Patient Advocate Foundation (PAF) is the leading patient advocacy group in the country, helping patients overcome insurance obstacles and access to care issues. But we are also advocates for physicians, who are often caught in the middle between the patient and their insurer. Come stop by Booth #8045 for a demonstration of PAF’s National Underinsured Resource Directory. This NEW online resource provides immediate access to our nation’s resources for the underinsured. Additionally, packets of information on this program are available.

Two additional publications are waiting for you:

We are here to help doctors and nurses help their patients.

When patients run out of options to access their care,

contact PAF directly: 1-800-532-5274 or

www.patientadvocate.org. To access PAF’s National Underinsured Resource

Directory, visit http://patientadvocate.org/

help4u.php.

12A • ASCO Daily News • SATURDAY, JUNE 5, 2010

New this year, The ASCO Cancer Foundation® awarded Improving Cancer Care Grants (ICCGs), funded

by Susan G. Komen for the Cure®, which pro-vide research funding to address important issues with a general applicability to breast cancer regarding health care access, quality of care, and delivery of care. A 3-year grant totaling $1.35 million, the ICCG is the largest award disbursed by the Foundation to date.

In 2010, two research teams received ICCGs to develop and implement new solu-tions to existing challenges in cancer care.

Ann Hart Partridge, MD, MPH, of Dana-Farber Cancer Institute, supported by Karen M. Emmons, PhD; Mary L. Greany, PhD; Kathryn J. Ruddy, MD, MPH; and Julie S. Najita, PhD, will address the issues and con-cerns facing young women undergoing breast cancer treatment — in particular, fertility con-cerns and preservation, genetic issues, and psychosocial distress. Researchers will imple-ment a program in community care settings to provide additional support and education for young women with breast cancer, and to provide additional education and clinical tools to assist providers in caring for these patients; the program will be evaluated in

comparison with another simi-lar intervention through a ran-domized con-trolled trial.

“We have de-veloped a Pro-gram for Young Women with Breast Cancer at our institution, Dana-Farber/Brigham and Women’s Cancer Center, and are excited about the opportu-nity to expand this unique program to sites throughout the country,” Dr. Partridge said in an interview with ASCO Daily News. “Further improved understanding on the part of pro-viders and patients about these issues should lead to targeted clinical interventions aimed at reducing distress and improving outcomes.”

Patricia Harrigan Hardenbergh, MD, of Shaw Regional Cancer Center, supported by co-investigator Carol A. Hahn, MD, of Duke University, will develop a program that uses a Web-based radiation oncology treatment-planning review program in an effort to con-nect small, rural radiation oncology practices

to the rapidly advancing tech-nology used in many larger group practices. Through this project, called “Chartrounds,” radiation oncolo-gists practicing in rural areas will be able to virtually collaborate with

some of the top breast radiation oncologists in the world, mimicking traditional patient chart reviews.

“In order to serve patients well, the com-munity oncologist must function as the ‘gen-eral practitioner’ of oncology and is expected to practice cutting-edge oncology for many different cancer diagnoses. In contrast, an oncologist practicing at a major cancer cen-ter will likely focus his or her career on one disease site and have several colleagues in the department doing the same,” Dr. Harden-bergh said in an email to ASCO Daily News. “We propose a system in which we can help community oncologists achieve access to

disease-site experts and offer top quality care to the 85% of patients with cancer who are treated in the community setting.”

Joseph S. Bailes, MD, Past Chair of The ASCO Cancer Foundation Board of Directors, echoed these sentiments regarding the impor-tance making high-quality care more acces-sible, noting, “Progress in cancer research is meaningless when patients don’t have access to the latest scientifi c discoveries. The Improv-ing Cancer Care Grant offers researchers the opportunity to go beyond discussing and ana-lyzing current problems and to begin devel-oping real solutions that will increase patient access to quality cancer care.”

Research Teams Receive $1.35 Million to Improve Patient Care

Ann Hart Partridge, MD, MPH Patricia Harrigan Hardenbergh, MD

New for 2010, the Networking & Connection Hub offers topic-based discussions, technology dem-

onstrations, and the opportunity to meet with ASCO leadership during sessions held throughout the day. Scheduled sessions with-in the Networking & Connection Hub in-clude demonstrations of e-book readers and smartphone applications; an introduction to ASCO’s social networking presence on Twit-ter, LinkedIn, and Facebook; and an ASCO Tweet Up. The Networking & Connection Hub is located in the back of the Oncology Professionals Hall near the Food Court, and provides a chance to network with your col-leagues and learn about the latest technology products and applications. Today’s schedule is listed below, and each subsequent issue of ASCO Daily News (through Monday) will contain a list of the day’s planned activities.

9:00 AM – 10:30 AM Networking Tools: Demonstration and Discussion of ASCO’s Mobile Applications

10:30 AM – 12:00 PM Introduction to the ASCO Connection and ASCO on Twitter, LinkedIn, and Facebook

12:00 PM – 1:30 PM Lunchtime Conversation

L. Michael Glodé, MD, Chair, ASCO Inte-grated Technology Committee

1:30 PM – 3:00 PM Networking Tools: Demonstration and Discussion of eReaders, including iPad, Kindle, and Nook

3:00 PM – 4:00 PM ASCO LinkedIn User Group Discussion

4:00 PM – 5:00 PM ASCO Tweet Up

Nine late-breaking abstracts (LBAs) and two Clinical Review Abstracts (CRAs) will be presented as part of

today’s Meeting program. Introduced during the 2009 Annual Meeting, CRAs are identi-fi ed as having potential important implica-tions for patient care.

Full-text versions of the Plenary abstracts, as well as of the LBAs and CRAs, can be found in the 2010 ASCO Annual Meeting Proceedings Part II. All LBAs and CRAs are available online at abstract.asco.org, beginning today at 12:00 PM EDT. Each issue of ASCO Daily News will contain a list of the LBAs and CRAs being pre-sented as part of that day’s Meeting program.

Clinical Science Symposium, Molecularly Targeted Trials in Lung Cancer8:00 AM – 9:30 AM • E Hall D1

8:30 AM“A randomized phase II trial of mapatu-mumab, a TRAIL-R1 agonist monoclonal an-tibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.” (Abstract LBA7501)Presenter: Joachim Von Pawel, MD

9:00 AM“Results from ARQ 197-209: A global ran-domized placebo-controlled phase II clini-cal trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).” (Abstract LBA7502)Presenter: Joan H. Schiller, MD

Oral Abstracts Session, Melanoma/Skin Cancers1:00 PM – 4:00 PM • S406 (Vista Room)

1:30 PM“Adjuvant therapy with pegylated inter-feron alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial.” (Abstract LBA8506)Presenter: Jean Jacques Grob

3:30 PM“A phase III random assignment trial com-paring percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from meta-static ocular or cutaneous melanoma.” (Ab-stract LBA8512)Presenter: James F. Pingpank, Jr., MD

Oral Abstract Session, Lung Cancer—Local-Regional and Adjuvant Therapy3:00 PM – 5:30 PM • E Hall D1

4:15 PM“A phase III, intergroup, randomized, dou-ble-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).” (Abstract CRA7004)Presenter: Daniel D. Karp, MD

4:30 PM“A phase III randomized, double-blind, pla-cebo-controlled trial of the epidermal growth factor receptor inhibitor gefi tinb in com-pletely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.” (Abstract LBA7005)Presenter: Glenwood D. Goss

5:00 PM“A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P)

and carboplatin (C) versus paclitaxel and car-boplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC).” (Ab-stract LBA7007)Presenter: Panos Fidias, MD

Oral Abstract Session, Central Nervous System Tumors3:00 PM – 6:00 PM • S100b

3:00 PM“NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-fi eld radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Me-thusalem).” (Abstract LBA2001)Presenter: Wolfgang Wick, MD

3:15 PM“Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing surviv-al in patients treated with 6-week radiother-apy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ).” (Abstract LBA2002)Presenter: Annika Malmstrom

5:00 PM“A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A ver-sus best standard of care chemotherapy in patients with recurrent glioblastoma.” (Ab-stract LBA2007)Presenter: Roger Stupp, MD

Clinical Science Symposium, Signaling in Pediatric Cancer Comes to the Clinic4:30 PM – 5:45 PM • S504

4:45 PM“A phase I pharmacokinetic trial of sonic hedge-hog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medullo-blastoma: A Pediatric Brain Tumor Consortium study (PBTC 25).” (Abstract CRA9501)Presenter: Amar J. Gajjar, MD

Late-breaking and Clinical Review Abstracts to Be Presented Today

Interact with Colleagues at the Networking & Connection Hub

Reception for Foundation Grants Alumni

The Foundation will host its fi rst-ever Grants Alumni Network-ing Reception this evening from

6:00 PM – 7:30 PM in the Associate and Active-Junior Lounge, Room S501. All grant recipients and Foundation grants alumni are invited to attend.

CLL8 TRIAL (N=817)

In relapsed/refractory* CLL2.1-year follow-up

In first-line CLL1.7-year follow-up

39.8 months

R-FC31.5 months

FCvs

REACH TRIAL (N=552)RITUXAN-NAIVE PATIENTS

26.7 months

R-FC21.7 months

FCvs

8.3month

improvementin median

PFS

5.0month

improvementin median

PFS

Indication RITUXAN® (Rituximab) is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.

RITUXAN is not recommended for use in patients with severe, active infections.

DRIVING BETTEROUTCOMESRITUXAN+FC improved median PFS in first-line and previously treated CLL1,2

In the CLL8 trial2

RITUXAN+FC more than doubled CR in first-line CLL compared with FC alone (36% vs 17%; p<0.0001)

In the REACH trial2

Patients who responded to RITUXAN+FC (n=167) maintained their responses for nearly 2 years longer (48 months vs 27 months; p=0.0294) than those treated with FC alone (n=134)

NOW IN THE TREATMENT OFCHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

BOXED WARNINGS and Additional Important Safety InformationRITUXAN therapy can result in serious, including fatal, adverse reactions. These include infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation with fulminant hepatitis, other infections, cardiovascular events, renal toxicity, and bowel obstruction and perforation.

The most common adverse reactions of RITUXAN (incidence ≥25%) observed in clinical trials of patients with CLL were infusion reactions and neutropenia. Most patients treated with R-FC experienced at least one Grade 3 or 4 adverse reaction. The most frequently reported Grade 3 or 4 adverse reaction was neutropenia.

In clinical trials, CLL patients 70 years of age or older who received R-FC had more Grade 3 and 4 adverse reactions compared with younger CLL patients who received the same treatment.

For additional safety information, please see following page for brief summary of full prescribing information, including BOXED WARNINGS.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

* In the REACH trial, patients had received 1 prior therapy. Patients who had previously received RITUXAN or both fludarabine and cyclophosphamide, either sequentially or in combination, were excluded from the trial, as were fludarabine-refractory patients; alkylator-refractory patients were permitted.2

R=RITUXAN; FC=fludarabine and cyclophosphamide; PFS=progression-free survival; CR=complete response.

Treatment considerationsThese trials were not designed or powered to detect a significant difference in PFS by age category. However, exploratory analyses defined by age suggest no observed benefit with the addition of RITUXAN to FC chemotherapy in previously untreated CLL patients 70 years of age or older and in previously treated CLL patients 65 years of age or older.1

©2010 Genentech USA, Inc., and Biogen Idec Inc. All rights reserved. 10021500 February 2010

References: 1. RITUXAN® (Rituximab) full prescribing information, Genentech, Inc., 2010. 2. Data on file, Genentech, Inc.

70227bi_a 1 4/6/10 11:04 PM

14A • ASCO Daily News • SATURDAY, JUNE 5, 2010

adverse reactions were defined by any of the following adverse events occurring during or within 24 hours of the start of infusion: nausea, pyrexia, chills, hypotension, vomiting,and dyspnea. In Study 9, the following Grade 3 and 4 adverse reactions occurred more frequently in R-FC–treated patients compared to FC-treated patients: infusion reactions (9% in R-FC arm), neutropenia (30% vs. 19%), febrile neutropenia (9% vs. 6%), leukopenia (23% vs. 12%), and pancytopenia (3% vs. 1%). In Study 10, the following Grade 3 or 4 adverse reactions occurred more frequently in R-FC–treated patients compared to FC-treated patients: infusion reactions (7% in R-FC arm), neutropenia (49% vs. 44%), febrile neutropenia (15% vs. 12%), thrombocytopenia (11% vs. 9%), hypotension (2% vs. 0%), and hepatitis B (2% vs. <1%). Fifty-nine percent of R-FC–treated patients experienced an infusion reaction of any severity. Immunogenicity As with all therapeutic proteins, ythere is a potential for immunogenicity. The observed incidence of antibody (including neutralizing antibody) positivity in an assay is highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Rituxan with the incidence of antibodies to other products may be misleading. Using an ELISA assay, anti-human anti-chimeric antibody (HACA) was detected in 4 of 356 (1.1%) patients with low-grade or follicular NHL receiving single-agent Rituxan. Three of the four patients had an objective clinical response. The clinical relevance of HACA formation in Rituxan-treated patients is unclear. Postmarketing Experience The following adverse reactions have beenidentified during post-approval use of Rituxan in hematologic malignancies. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to Rituxan. Hematologic: prolonged :pancytopenia, marrow hypoplasia, and late-onset neutropenia, hyperviscosity syndrome in Waldenstrom’s macroglobulinemia. Cardiac: fatal cardiac failure. : Immune/Autoimmune Events: uveitis, optic neuritis, systemic vasculitis, pleuritis, lupus-like :syndrome, serum sickness, polyarticular arthritis, and vasculitis with rash. Infection: viral :infections, including progressive multifocal leukoencephalopathy (PML), increase in fatal infections in HIV-associated lymphoma, and a reported increased incidence of Grade 3 and 4 infections in patients with previously treated lymphoma without known HIV infection. Neoplasia: disease progression of Kaposi’s sarcoma.: Skin: severe mucocutaneous:reactions. Gastrointestinal: bowel obstruction and perforation. : Pulmonary: fatal:bronchiolitis obliterans and pneumonitis (including interstitial pneumonitis). DRUGINTERACTIONS Formal drug interaction studies have not been performed with Rituxan. In patients with CLL, Rituxan did not alter systemic exposure to fludarabine or cyclophosphamide. USE IN SPECIFIC POPULATIONS Pregnancy Category C: There are no adequate and well-controlled studies of rituximab in pregnant women. Postmarketing data indicate that B-cell lymphocytopenia generally lasting less than six months can occur in infants exposed to rituximab in-utero. Rituximab was detected postnatally in the serum of infants exposed in-utero. Non-Hodgkin’s lymphoma is a serious condition that requires treatment. Rituximab should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. Reproduction studies in cynomolgus monkeys at maternal exposures similar to human therapeutic exposures showed no evidence of teratogenic effects. However, B-cell lymphoid tissue was reduced in the offspring of treated dams. The B-cell counts returned to normal levels, and immunologic function was restored within 6 months of birth. Nursing Mothers It is not known whether Rituxan is secreted into human milk.However, Rituxan is secreted in the milk of lactating cynomolgus monkeys, and IgG is excreted in human milk. Published data suggest that antibodies in breast milk do not enter the neonatal and infant circulations in substantial amounts. The unknown risks to the infant from oral ingestion of Rituxan should be weighed against the known benefits of breast-feeding. Pediatric Use The safety and effectiveness of Rituxan in pediatric patients have not been established. Geriatric Use Diffuse Large B-Cell NHL AmongLpatients with DLBCL evaluated in three randomized, active-controlled trials, 927 patients received Rituxan in combination with chemotherapy. Of these, 396 (43%) were age 65 or greater and 123 (13%) were age 75 or greater. No overall differences in effectiveness were observed between these patients and younger patients. Cardiac adverse reactions, mostly supraventricular arrhythmias, occurred more frequently among elderly patients. Serious pulmonary adverse reactions were also more common among the elderly, including pneumonia and pneumonitis. Low-Grade or Follicular Non-Hodgkin’s Lymphoma Clinical studies of Rituxan in low-grade or follicular, CD20-positive, B-cell NHL did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger subjects. Chronic Lymphocytic LeukemiaAmong patients with CLL evaluated in two randomized active-controlled trials, 243 of 676 Rituxan-treated patients (36%) were 65 years of age or older; of these, 100 Rituxan-treated patients (15%) were 70 years of age or older. In exploratory analyses defined by age, there was no observed benefit from the addition of Rituxan to fludarabine and cyclophosphamide among patients 70 years of age or older in Study 9 or in Study 10; there was also no observed benefit from the addition of Rituxan to fludarabine and cyclophosphamide among patients 65 years of age or older in Study 10 [see Clinical Studies]. Patients 70 years or older received lower dose intensity of fludarabine andscyclophosphamide compared to younger patients, regardless of the addition of Rituxan. In Study 9, the dose intensity of Rituxan was similar in older and younger patients, however in Study 10 older patients received a lower dose intensity of Rituxan. The incidence of Grade 3 and 4 adverse reactions was higher among patients receiving R-FC who were 70 years or older compared to younger patients for neutropenia [44% vs. 31% (Study 9); 56% vs. 39% (Study 10)], febrile neutropenia [16% vs. 6% (Study 9)], anemia [5% vs. 2% (Study 9); 21% vs. 10% (Study 10)], thrombocytopenia [19% vs. 8% (Study 10)], pancytopenia [7% vs. 2% (Study 9); 7% vs. 2% (Study 10)] and infections [30% vs. 14% (Study 10)]. OVERDOSAGE There has been no experience with overdosage in human clinical trials. Single doses of up to 500 mg/m2 have been administered in clinical trials. NONCLINICAL TOXICOLOGY Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to establish the carcinogenicyor mutagenic potential of Rituxan or to determine potential effects on fertility in males or females. PATIENT COUNSELING INFORMATION Patients should be provided theRituxan Medication Guide and provided an opportunity to read prior to each treatment session. It is important that the patient’s overall health be assessed at each visit and the risks of Rituxan therapy and any questions resulting from the patient’s reading of the Medication Guide be discussed. Rituxan is detectable in serum for up to six months following completion of therapy. Individuals of childbearing potential should use effective contraception during treatment and for 12 months after Rituxan therapy.

Revised 02/2010 (4851501)

Jointly Marketed by:Biogen Idec Inc. 5200 Research Place San Diego, CA 92122Genentech USA, Inc. 1 DNA Way South San Francisco, CA 94080-4990

©2010 Biogen Idec Inc. and Genentech, Inc. 7140919 February 2010

RITUXAN® (Rituximab) Brief summary—Please consult full prescribing information.

INDICATIONS AND USAGE Non-Hodgkin’s Lymphoma (NHL) Rituxan® (rituximab) isindicated for the treatment of patients with: Relapsed or refractory, low-grade orfollicular, CD20-positive, B-cell NHL as a single agent; Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy; Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, afterfirst-line CVP chemotherapy; Previously untreated diffuse large B-cell, CD20-positiveNHL in combination with CHOP or other anthracycline-based chemotherapy regimens.Chronic Lymphocytic Leukemia (CLL) Rituxan® (rituximab) is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patientswith previously untreated and previously treated CD20-positive CLL. Limitations of useRituxan is not recommended for use in patients with severe, active infections.WARNINGS AND PRECAUTIONS Infusion Reactions Rituxan can cause severe,including fatal, infusion reactions. Severe reactions typically occurred during the firstinfusion with time to onset of 30–120 minutes. Rituxan-induced infusion reactions andsequelae include urticaria, hypotension, angioedema, hypoxia, bronchospasm,pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction,ventricular fibrillation, cardiogenic shock, anaphylactoid events, or death. Premedicate patients with an antihistamine and acetaminophen prior to dosing. Institute medicalmanagement (e.g. glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusionreactions as needed. Depending on the severity of the infusion reaction and the requiredinterventions, temporarily or permanently discontinue Rituxan. Resume infusion at aminimum 50% reduction in rate after symptoms have resolved. Closely monitor thefollowing patients: those with pre-existing cardiac or pulmonary conditions, those whoexperienced prior cardiopulmonary adverse reactions, and those with high numbers ofcirculating malignant cells (≥25,000/mm3). [See Boxed Warning, Warnings and Precautions, Adverse Reactions.] Tumor Lysis Syndrome (TLS) Acute renal failure,hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis,some fatal, can occur within 12–24 hours after the first infusion of Rituxan in patientswith NHL. A high number of circulating malignant cells (≥25,000/mm3) or high tumor burdenconfers a greater risk of TLS. Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for TLS. Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated. [See Boxed Warning.] Severe Mucocutaneous Reactions Mucocutaneous reactions, some with fatal outcome, can occur in patients treated with Rituxan. Thesereactions include paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoiddermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis. The onset of these reactions has varied from 1–13 weeks following Rituxan exposure. Discontinue Rituxan in patients who experience a severe mucocutaneous reaction. The safety ofreadministration of Rituxan to patients with severe mucocutaneous reactions has notbeen determined. [See Boxed Warning, Adverse Reactions.] Progressive MultifocalLeukoencephalopathy (PML) JC virus infection resulting in PML and death can occur in Rituxan-treated patients with hematologic malignancies or with autoimmune diseases.The majority of patients with hematologic malignancies diagnosed with PML receivedRituxan in combination with chemotherapy or as part of a hematopoietic stem celltransplant. The patients with autoimmune diseases had prior or concurrentimmunosuppressive therapy. Most cases of PML were diagnosed within 12 months oftheir last infusion of Rituxan. Consider the diagnosis of PML in any patient presentingwith new-onset neurologic manifestations. Evaluation of PML includes, but is not limitedto, consultation with a neurologist, brain MRI, and lumbar puncture. Discontinue Rituxanand consider discontinuation or reduction of any concomitant chemotherapy orimmunosuppressive therapy in patients who develop PML. [See Boxed Warning, Adverse Reactions.] Hepatitis B Virus (HBV) Reactivation Hepatitis B virus (HBV) reactivation with fulminant hepatitis, hepatic failure, and death can occur in patients with hematologicmalignancies treated with Rituxan. The median time to the diagnosis of hepatitis wasapproximately 4 months after the initiation of Rituxan and approximately one month afterthe last dose. Screen patients at high risk of HBV infection before initiation of Rituxan.Closely monitor carriers of hepatitis B for clinical and laboratory signs of active HBVinfection for several months following Rituxan therapy. Discontinue Rituxan and anyconcomitant chemotherapy in patients who develop viral hepatitis, and instituteappropriate treatment including antiviral therapy. Insufficient data exist regarding thesafety of resuming Rituxan in patients who develop hepatitis subsequent to HBVreactivation. [See Adverse Reactions.] Infections Serious, including fatal, bacterial,fungal, and new or reactivated viral infections can occur during and up to one yearfollowing the completion of Rituxan-based therapy. New or reactivated viral infectionsincluded cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C. Discontinue Rituxan for serious infections and institute appropriate anti-infective therapy. [See Adverse Reactions.] CardiovascularDiscontinue infusions for serious or life-threatening cardiac arrhythmias. Perform cardiac monitoring during and after all infusions of Rituxan for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina. [See Adverse Reactions.] Renal Severe, including fatal, renal toxicity can occur after Rituxanadministration in patients with NHL. Renal toxicity has occurred in patients whoexperience tumor lysis syndrome and in patients with NHL administered concomitantcisplatin therapy during clinical trials. The combination of cisplatin and Rituxan is not anapproved treatment regimen. Monitor closely for signs of renal failure and discontinueRituxan in patients with a rising serum creatinine or oliguria. Bowel Obstruction and Perforation Abdominal pain, bowel obstruction and perforation, in some cases leadingto death, can occur in patients receiving Rituxan in combination with chemotherapy. Inpostmarketing reports, the mean time to documented gastrointestinal perforation was 6(range 1–77) days in patients with NHL. Perform a thorough diagnostic evaluation andinstitute appropriate treatment for complaints of abdominal pain. [See Adverse Reactions.] Immunization The safety of immunization with live viral vaccines followingRituxan therapy has not been studied and vaccination with live virus vaccines is notrecommended. Laboratory Monitoring In patients with lymphoid malignancies, duringtreatment with Rituxan monotherapy, obtain complete blood counts (CBC) and platelet

WARNING: FATAL INFUSION REACTIONS, TUMOR LYSIS SYNDROME (TLS), SEVERE MUCOCUTANEOUS REACTIONS, and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)Infusion Reactions: Rituxan administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Carefully monitor patients during infusions. Discontinue Rituxan infusion and provide medical treatment for Grade 3 or 4 infusion reactions [see Warnings and Precautions, Adverse Reactions]. s Tumor Lysis Syndrome (TLS): Acute renal failure requiring dialysis with instances of fatal outcome can occur in the setting of TLS following treatment of non-Hodgkin’s lymphoma (NHL) patients with Rituxan [see Warnings and Precautions, Adverse Reactions].ss Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan [see Warnings and Precautions, Adverse Reactions]. s Progressive Multifocal Leukoen cephalopathy (PML): JC virus infection resulting in PML and death can occur in patients receiving Rituxan [see Warnings and Precautions, Adverse Reactions].ss

counts prior to each Rituxan course. During treatment with Rituxan and chemotherapy,obtain CBC and platelet counts at weekly to monthly intervals and more frequently in patients who develop cytopenias. [See Adverse Reactions]. The duration of cytopeniasscaused by Rituxan can extend months beyond the treatment period. ADVERSEREACTIONS The most common adverse reactions of Rituxan (incidence ≥25%)observed in clinical trials of patients with NHL were infusion reactions, fever, lymphopenia, chills, infection, and asthenia. The most common adverse reactions of Rituxan (incidence ≥25%) observed in clinical trials of patients with CLL were: infusion reactions and neutropenia. Clinical Trials Experience in Lymphoid MalignanciesBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to Rituxan in 2282 patients, with exposures ranging from a single infusion up to 6–8 months. Rituxan was studied in both single-agent and active-controlled trials (n = 356 and n = 1926). The population included 679 patients with low-grade follicular lymphoma, 927 patients with DLBCL, and 676 patients with CLL. Most NHL patients received Rituxan as infusion of 375 mg/m2 per infusion, given as a single agent weekly for up to 8 doses, in combination with chemotherapy for up to 8 doses, or following chemotherapy for up to 16 doses. CLL patients received Rituxan 375 mg/m2 as an initial infusion followed by 500 mg/m2 for up to 5 doses, in combination withfludarabine and cyclophosphamide. Seventy-one percent of CLL patients received 6 cycles and 90% received at least 3 cycles of Rituxan-based therapy. Infusion Reactions In the majority of patients with NHL, infusion reactions consisting of fever,schills/rigors, nausea, pruritus, angioedema, hypotension, headache, bronchospasm, urticaria, rash, vomiting, myalgia, dizziness, or hypertension occurred during the first Rituxan infusion. Infusion reactions typically occurred within 30 to 120 minutes of beginning the first infusion and resolved with slowing or interruption of the Rituxan infusion and with supportive care (diphenhydramine, acetaminophen, and intravenous saline). The incidence of infusion reactions was highest during the first infusion (77%) and decreased with each subsequent infusion. [See Boxed Warning, Warnings and Precautions.] Infections Serious infections (NCI CTCAE Grade 3 or 4), including sepsis,occurred in less than 5% of patients with NHL in the single-arm studies. The overall incidence of infections was 31% (bacterial 19%, viral 10%, unknown 6%, and fungal 1%). [See Warnings and Precautions.] In randomized, controlled studies where Rituxanwas administered following chemotherapy for the treatment of follicular or low-grade NHL, the rate of infection was higher among patients who received Rituxan. In diffuse large B-cell lymphoma patients, viral infections occurred more frequently in those who received Rituxan. Cytopenias and hypogammaglobulinemia In patients with NHL areceiving rituximab monotherapy, NCI-CTC Grade 3 and 4 cytopenias were reported in 48% of patients. These included lymphopenia (40%), neutropenia (6%), leukopenia (4%), anemia (3%), and thrombocytopenia (2%). The median duration of lymphopenia was 14 days (range, 1–588 days) and of neutropenia was 13 days (range, 2–116 days). A single occurrence of transient aplastic anemia (pure red cell aplasia) and two occurrences of hemolytic anemia following Rituxan therapy occurred during the single-arm studies. In studies of monotherapy, Rituxan-induced B-cell depletion occurred in 70% to 80% of patients with NHL. Decreased IgM and IgG serum levels occurred in 14% of these patients. Relapsed or Refractory, Low-Grade NHL Adverse reactions in Table 1occurred in 356 patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL treated in single-arm studies of Rituxan administered as a single agent. [See Clinical Studies.] Most patients received Rituxan 375 mg/m2 weekly for 4 doses.Table 1Incidence of Adverse Reactions in ≥5% of Patients with Relapsed or Refractory, Low-Grade or Follicular NHL, Receiving Single-agent Rituxan (N = 356)a,b

aAdverse reactions observed up to 12 months following Rituxan. bAdverse reactions graded for severity by NCI-CTC criteria.

In these single-arm Rituxan studies, bronchiolitis obliterans occurred during and up to 6 months after Rituxan infusion. Previously Untreated Low-Grade NHL In Study 4,Lpatients in the R-CVP arm experienced a higher incidence of infusional toxicity and neutropenia compared to patients in the CVP arm. The following adverse reactions occurred more frequently (≥5%) in patients receiving R-CVP compared to CVP alone: rash (17% vs. 5%), cough (15% vs. 6%), flushing (14% vs. 3%), rigors (10% vs. 2%), pruritus (10% vs. 1%), neutropenia (8% vs. 3%), and chest tightness (7% vs. 1%). In Study 5, the following adverse reactions were reported more frequently (≥5%) in patients receiving Rituxan following CVP compared to patients who received no furthertherapy: fatigue (39% vs. 14%), anemia (35% vs. 20%), peripheral sensory neuropathy (30% vs. 18%), infections (19% vs. 9%), pulmonary toxicity (18% vs. 10%), hepato-biliary toxicity (17% vs. 7%), rash and/or pruritus (17% vs. 5%), arthralgia (12% vs. 3%), and weight gain (11% vs. 4%). Neutropenia was the only Grade 3 or 4 adverse reaction that occurred more frequently (≥2%) in the Rituxan armcompared with those who received no further therapy (4% vs. 1%). [See Clinical Studies.] DLBCL In Studies 6 and 7, [L see Clinical Studies]s the following adverse reactions,regardless of severity, were reported more frequently (≥5%) in patients age ≥60 yearsreceiving R-CHOP as compared to CHOP alone: pyrexia (56% vs. 46%), lung disorder (31% vs. 24%), cardiac disorder (29% vs. 21%), and chills (13% vs. 4%). Detailed safety data collection in these studies was primarily limited to Grade 3 and 4 adverse reactions and serious adverse reactions. In Study 7, a review of cardiac toxicity determined that supraventricular arrhythmias or tachycardia accounted for most of the difference in cardiac disorders (4.5% for R-CHOP vs. 1.0% for CHOP). The following Grade 3 or 4 adverse reactions occurred more frequently among patients in the R-CHOP arm compared with those in the CHOP arm: thrombocytopenia (9% vs. 7%) and lung disorder (6% vs. 3%). Other Grade 3 or 4 adverse reactions occurring more frequently among patients receiving R-CHOP were viral infection (Study 7), neutropenia (Studies 7 and 8), and anemia (Study 8). CLL The data below reflectLexposure to Rituxan in combination with fludarabine and cyclophosphamide in 676 patients with CLL in Study 9 or Study 10 [see Clinical Studies]. The age range was s30–83 years and 71% were men. Detailed safety data collection in Study 9 was limited to Grade 3 and 4 adverse reactions and serious adverse reactions. Infusion-related

All Grades (%) Grade 3 and 4 (%)

Any Adverse Events 99 57Body as a Wholey 86 10

Fever 53 1Chills 33 3Infection 31 4Asthenia 26 1Headache 19 1Abdominal Pain 14 1Pain 12 1Back Pain 10 1Throat Irritation 9 0Flushing 5 0

Heme and Lymphatic Systemy p y 67 48Lymphopenia 48 40Leukopenia 14 4Neutropenia 14 6Thrombocytopenia 12 2Anemia 8 3

Skin and Appendagespp g 44 2Night Sweats 15 1Rash 15 1Pruritus 14 1Urticaria 8 1

All Grades (%) Grade 3 and 4 (%)

Respiratory Systemp y y 38 4Increased Cough 13 1Rhinitis 12 1Bronchospasm 8 1Dyspnea 7 1Sinusitis 6 0

Metabolic and NutritionalDisorders 38 3

Angioedema 11 1Hyperglycemia 9 1Peripheral Edema 8 0LDH Increase 7 0

Digestive Systemg y 37 2Nausea 23 1Diarrhea 10 1Vomiting 10 1

Nervous Systemy 32 1Dizziness 10 1Anxiety 5 1

Musculoskeletal Systemy 26 3Myalgia 10 1Arthralgia 10 1

Cardiovascular Systemy 25 3Hypotension 10 1Hypertension 6 1

70227bi_a 2 4/6/10 11:04 PM

At the 2009 ASCO Annual Meeting, attendees recycled 175 tons of mate-rial that would otherwise have been

thrown away. In an effort to continue to be environmentally responsible and to minimize the Annual Meeting’s effect on the environ-ment, ASCO and McCormick Place have a number of initiatives in place.

Recycling tables — easily identifi able by their green tablecloths — will be located near Registration and at all tote bag pick-up locations to make recycling Annual Meeting products convenient and straightforward. At-tendees are welcome to leave unwanted print

products in these areas.New this year, water stations will be lo-

cated in the various lounges and committee meeting rooms throughout McCormick Place to reduce waste at the Meeting. Attendees are encouraged to bring their own eco-friendly water bottles and to refi ll their containers at any of the stations. Recycling bins for cans and bottles are located throughout McCor-mick Place as well.

In addition to these efforts to reduce waste and recycle, the tote bags distributed onsite are constructed from 100% recycled materi-als and the print versions of Annual Meeting

products are published on post-consumer re-cycled paper.

Also new in 2010, the print versions of the 2010 ASCO Educational Book and the 2010 ASCO Annual Meeting Proceedings Part I will not be automatically included in every tote bag. Rather, when picking up tote bags after arriving in Chicago, attendees will be asked whether they would like to receive these materials in print or to receive ASCO’s new eTote, which features both products in an electronic format on a USB drive (or online at www.asco.org/eTote2010).

Along with ASCO’s environmentally con-

scious strategies, McCormick Place has sev-eral measures in place to ensure that the venue is a steward of the environment. Com-pact fl uorescent bulbs, energy-effi cient heat-ing and air conditioning systems, and Green Seal cleaning products are used throughout the center. At all food service locations, bio-degradable fl atware, straws, serving dishes, and cups are used as a greener alternative to Styrofoam or polystyrene plastic.

Additionally, McCormick Place is powered in part by electricity from renewable sources. The facility features one of the largest green roofs in Chicago — maintained with a highly effi cient irrigation system — with 40,000 plants improving air quality and helping to reduce the city’s heat island effect.

Environmental Efforts at ASCO’s Annual Meeting

Attendees now have access to the most important Annual Meeting information on the go. New for

the 2010 ASCO Annual Meeting, attend-ees can download the eGuide™ Annual Meeting Program application straight to their mobile device.

The eGuide™ contains the complete 2010 Annual Meeting Program, and us-ers are invited to browse through the content or search the entire Meeting Program for sessions of interest; users may also add session times to the de-vice’s calendar. A complete, searchable listing of all exhibitors and their booth locations within the Oncology Profes-sionals Hall is also included in the ap-plication.

The eGuide™ is available for down-load on the iPhone, iPod Touch, iPad, Blackberry, Android, Windows Mo-bile, Palm, and Palm Pre. It can also be downloaded to a computer desktop. To access this new application, including complete instructions on how to use this tool, visit m.asco.org on any mo-bile device.

Technical support is available at the Mobile Applications Help Desk in Mc-Cormick Place — located in the North Building, Level 2.5 — for attendees who have questions about downloading the application to their mobile device.

eGuide™ Mobile Application Available for Annual Meeting Attendees

Unmet needs.

Unmet needs met.

That’s our focus at EMD Serono.

©201

0 E

MD

Ser

on

o, I

nc.www.emdserono.com

EMD Serono, Inc., an affiliate of Merck

KGaA, Darmstadt, Germany, has a global

commitment to developing new therapeutic

options for people living with cancer. We are

focused on developing novel cancer therapies

that combine approaches targeting the tumor

cell, tumor environment and immune system

to optimize treatment outcomes.

We’ve developed leading medicines for

multiple sclerosis, fertility, growth hormone

deficiency and HIV-associated wasting. We’re

one of the world’s leading biopharmaceutical

companies. And our values are reflected not

only in our products, but in our programs of

patient education and support, such as MS

LifeLines®, Fertility LifeLines™, SeroCareSM and

Connections for Growth®.

The people of EMD Serono are focused on

significant unmet medical needs. Meeting

them. And helping people live more fully.

Embracing life. Enhancing life. That is the spirit

of EMD Serono.

passion ignites progress

At Eisai Oncology, we have a passion for people.

Helping them reach their goals is what drives us to search for new discoveries.

It’s what ignites us to make a difference and have an impact. Delivering the progressthat innovative drug therapies bring to patients all over the world,

for us, is where every day begins.

PLEASE VISIT US AT BOOTH #18063

ONC9 ©2010 Eisai Inc. All rights reserved. June 2010 www.Eisai.com

Our passion ignites progress